United States securities and exchange commission logo





                          May 16, 2023

       Daniel R. Passeri
       Chief Executive Officer
       Cue Biopharma, Inc.
       40 Guest Street
       Boston, MA 02135

                                                        Re: Cue Biopharma, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed May 9, 2023
                                                            File No. 333-271786

       Dear Daniel R. Passeri:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Tyler
Howes at 202-551-3370 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Caroline Dotolo, Esq.